drugset / Trial / NCT07161193
Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Autoimmune Diseases
Phase 1/2
Not yet recruiting
30 enrolled
Hebei Senlang Biotechnology Inc., Ltd.
Henan Province Engineering Technology Research Center of Immunological Precision Medicine and Artificial Intelligence Application, Luoyang, China · collabThe Second Affiliated Hospital of Henan University of Traditional Chinese Medicine · collab
NaSingle-groupOpen-labelTreatment
Summary
The goal of this study is to evaluate the safety and efficacy of CD19 CAR T cells in the treatment of Refractory Autoimmune Diseases
Timeline
- Start
- 2025-09-30
- Primary completion
- 2027-08-18
- Completion
- 2027-11-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD19 CAR-T cells | Cell therapy | — | — |